Literature DB >> 33377124

Vascular Tumor Recapitulated in Endothelial Cells from hiPSCs Engineered to Express the SERPINE1-FOSB Translocation.

David G P van IJzendoorn1, Daniela C F Salvatori2, Xu Cao3, Francijna van den Hil3, Inge H Briaire-de Bruijn1, Danielle de Jong4, Hailiang Mei5, Christine L Mummery3, Karoly Szuhai4, Judith V M G Bovée1, Valeria V Orlova3.   

Abstract

Chromosomal translocations are prevalent among soft tissue tumors, including those of the vasculature such as pseudomyogenic hemangioendothelioma (PHE). PHE shows endothelial cell (EC) features and has a tumor-specific t(7;19)(q22;q13) SERPINE1-FOSB translocation, but is difficult to study as no primary tumor cell lines have yet been derived. Here, we engineer the PHE chromosomal translocation into human induced pluripotent stem cells (hiPSCs) using CRISPR/Cas9 and differentiate these into ECs (hiPSC-ECs) to address this. Comparison of parental with PHE hiPSC-ECs shows (1) elevated expression of FOSB, (2) higher proliferation and more tube formation but lower endothelial barrier function, (3) invasive growth and abnormal vessel formation in mice after transplantation, and (4) specific transcriptome alterations reflecting PHE and indicating PI3K-Akt and MAPK signaling pathways as possible therapeutic targets. The modified hiPSC-ECs thus recapitulate functional features of PHE and demonstrate how these translocation models can be used to understand tumorigenic mechanisms and identify therapeutic targets.
© 2020 The Author(s).

Entities:  

Keywords:  CRISPR/Cas9-mediated gene targeting; PHE; chromosomal translocation; endothelial cell differentiation; gene fusion; hiPSC-ECs; hiPSC-derived ECs; hiPSCs; human induced pluripotent stem cells; pseudomyogenic hemangioendothelioma; t(7;19)(q22;q13) SERPINE1-FOSB chromosomal translocation; tumor model; vascular tumor

Mesh:

Substances:

Year:  2020        PMID: 33377124      PMCID: PMC7762773          DOI: 10.1016/j.xcrm.2020.100153

Source DB:  PubMed          Journal:  Cell Rep Med        ISSN: 2666-3791


  39 in total

1.  GMAP: a genomic mapping and alignment program for mRNA and EST sequences.

Authors:  Thomas D Wu; Colin K Watanabe
Journal:  Bioinformatics       Date:  2005-02-22       Impact factor: 6.937

2.  Fiji: an open-source platform for biological-image analysis.

Authors:  Johannes Schindelin; Ignacio Arganda-Carreras; Erwin Frise; Verena Kaynig; Mark Longair; Tobias Pietzsch; Stephan Preibisch; Curtis Rueden; Stephan Saalfeld; Benjamin Schmid; Jean-Yves Tinevez; Daniel James White; Volker Hartenstein; Kevin Eliceiri; Pavel Tomancak; Albert Cardona
Journal:  Nat Methods       Date:  2012-06-28       Impact factor: 28.547

3.  Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior.

Authors:  Jason L Hornick; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2011-02       Impact factor: 6.394

Review 4.  Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themes.

Authors:  Fredrik Mertens; Cristina R Antonescu; Felix Mitelman
Journal:  Genes Chromosomes Cancer       Date:  2015-12-18       Impact factor: 5.006

Review 5.  The Fos family of transcription factors and their role in tumourigenesis.

Authors:  Karin Milde-Langosch
Journal:  Eur J Cancer       Date:  2005-09-30       Impact factor: 9.162

6.  Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy.

Authors:  Anna Rita Cantelmo; Lena-Christin Conradi; Aleksandra Brajic; Jermaine Goveia; Joanna Kalucka; Andreas Pircher; Pallavi Chaturvedi; Johanna Hol; Bernard Thienpont; Laure-Anne Teuwen; Sandra Schoors; Bram Boeckx; Joris Vriens; Anna Kuchnio; Koen Veys; Bert Cruys; Lise Finotto; Lucas Treps; Tor Espen Stav-Noraas; Francesco Bifari; Peter Stapor; Ilaria Decimo; Kim Kampen; Katrien De Bock; Guttorm Haraldsen; Luc Schoonjans; Ton Rabelink; Guy Eelen; Bart Ghesquière; Jalees Rehman; Diether Lambrechts; Asrar B Malik; Mieke Dewerchin; Peter Carmeliet
Journal:  Cancer Cell       Date:  2016-11-17       Impact factor: 31.743

7.  Induction of pluripotent stem cells from adult human fibroblasts by defined factors.

Authors:  Kazutoshi Takahashi; Koji Tanabe; Mari Ohnuki; Megumi Narita; Tomoko Ichisaka; Kiichiro Tomoda; Shinya Yamanaka
Journal:  Cell       Date:  2007-11-30       Impact factor: 41.582

8.  A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic haemangioendothelioma.

Authors:  Charles Walther; Johnbosco Tayebwa; Henrik Lilljebjörn; Linda Magnusson; Jenny Nilsson; Fredrik Vult von Steyern; Ingrid Øra; Henryk A Domanski; Thoas Fioretos; Karolin H Nord; Christopher D M Fletcher; Fredrik Mertens
Journal:  J Pathol       Date:  2014-01-29       Impact factor: 7.996

9.  Rapid and efficient one-step generation of paired gRNA CRISPR-Cas9 libraries.

Authors:  Joana A Vidigal; Andrea Ventura
Journal:  Nat Commun       Date:  2015-08-17       Impact factor: 14.919

10.  No Identical "Mesenchymal Stem Cells" at Different Times and Sites: Human Committed Progenitors of Distinct Origin and Differentiation Potential Are Incorporated as Adventitial Cells in Microvessels.

Authors:  Benedetto Sacchetti; Alessia Funari; Cristina Remoli; Giuseppe Giannicola; Gesine Kogler; Stefanie Liedtke; Giulio Cossu; Marta Serafini; Maurilio Sampaolesi; Enrico Tagliafico; Elena Tenedini; Isabella Saggio; Pamela G Robey; Mara Riminucci; Paolo Bianco
Journal:  Stem Cell Reports       Date:  2016-06-14       Impact factor: 7.765

View more
  2 in total

1.  Pazopanib as Treatment Option for Pseudomyogenic Hemangioendothelioma: A Case Report.

Authors:  Ali Alhanash; Mohamed Aseafan; Jean Atallah
Journal:  Cureus       Date:  2022-05-23

2.  Identification of stable housekeeping genes for induced pluripotent stem cells and -derived endothelial cells for drug testing.

Authors:  Sheena L M Ong; Hans J Baelde; David G P van IJzendoorn; Judith V M G Bovée; Karoly Szuhai
Journal:  Sci Rep       Date:  2022-09-28       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.